Introduction Pazopanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. to 600 mg daily. In arm A of 9 evaluable patients there was 1(11%) patient with a PSA response 3 (33%) with stable PSA and 5 (56%) with PSA progression; in arm B of 12 evaluable patients: there were 2 (17%)… Continue reading Introduction Pazopanib is an oral vascular endothelial growth factor receptor (VEGFR)